Optimization of cosmesis in parathyroidectomy

W. Ng

DOI: https://doi.org/10.1007/s00464-002-8524-4

2002-09-01

Surgical Endoscopy

Abstract:

What problem does this paper attempt to address?

Establishment of transgenic pigs overexpressing human PKD2-D511V mutant

Yuan Zhang,Saifei Xu,Qiao Jin,Jianing Luo,Ce Gao,Sakthidasan Jayaprakash,Huanan Wang,Lenan Zhuang,Jin He

DOI: https://doi.org/10.3389/fgene.2022.1059682

IF: 3.7

2022-01-01

Frontiers in Genetics

Abstract:Numerous missense mutations have been reported in autosomal dominant polycystic kidney disease which is one of the most common renal genetic disorders. The underlying mechanism for cystogenesis is still elusive, partly due to the lack of suitable animal models. Currently, we tried to establish a porcine transgenic model overexpressing human PKD2-D511V (hPKD2-D511V), which is a dominant-negative mutation in the vertebrate in vitro models. A total of six cloned pigs were finally obtained using somatic cell nuclear transfer. However, five with functional hPKD2-D511V died shortly after birth, leaving only one with the dysfunctional transgenic event to survive. Compared with the WT pigs, the demised transgenic pigs had elevated levels of hPKD2 expression at the mRNA and protein levels. Additionally, no renal malformation was observed, indicating that hPKD2-D511V did not alter normal kidney development. RNA-seq analysis also revealed that several ADPKD-related pathways were disturbed when overexpressing hPKD2-D511V. Therefore, our study implies that hPKD2-D511V may be lethal due to the dominant-negative effect. Hence, to dissect how PKD2-D511V drives renal cystogenesis, it is better to choose in vitro or invertebrate models.
Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD

Shin-Ichi Mae,Fumihiko Hattanda,Hiroyoshi Morita,Aya Nozaki,Naoko Katagiri,Hanako Ogawa,Kaori Teranaka,Yu Nishimura,Aoi Kudoh,Sanae Yamanaka,Kyoko Matsuse,Makoto Ryosaka,Akira Watanabe,Tomoyoshi Soga,Saori Nishio,Kenji Osafune

DOI: https://doi.org/10.1016/j.celrep.2023.113431

2023-12-26

Abstract:In autosomal dominant polycystic kidney disease (ADPKD), renal cyst lesions predominantly arise from collecting ducts (CDs). However, relevant CD cyst models using human cells are lacking. Although previous reports have generated in vitro renal tubule cyst models from human induced pluripotent stem cells (hiPSCs), therapeutic drug candidates for ADPKD have not been identified. Here, by establishing expansion cultures of hiPSC-derived ureteric bud tip cells, an embryonic precursor that gives rise to CDs, we succeed in advancing the developmental stage of CD organoids and show that all CD organoids derived from PKD1-/- hiPSCs spontaneously develop multiple cysts, clarifying the initiation mechanisms of cystogenesis. Moreover, we identify retinoic acid receptor (RAR) agonists as candidate drugs that suppress in vitro cystogenesis and confirm the therapeutic effects on an ADPKD mouse model in vivo. Therefore, our in vitro CD cyst model contributes to understanding disease mechanisms and drug discovery for ADPKD.
A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs

Tatsuya Shimizu,Shin-Ichi Mae,Toshikazu Araoka,Keisuke Okita,Akitsu Hotta,Kunihiro Yamagata,Kenji Osafune

DOI: https://doi.org/10.1016/j.bbrc.2020.06.141

2020-09-03

Abstract:Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder which manifests progressive renal cyst formation and leads to end-stage kidney disease. Around 85% of cases are caused by PKD1 heterozygous mutations, exhibiting relatively poorer renal outcomes than those with mutations in other causative gene PKD2. Although many disease models have been proposed for ADPKD, the pre-symptomatic pathology of the human disease remains unknown. To unveil the mechanisms of early cytogenesis, robust and genetically relevant human models are needed. Here, we report a novel ADPKD model using kidney organoids derived from disease-specific human induced pluripotent stem cells (hiPSCs). Importantly, we found that kidney organoids differentiated from gene-edited heterozygous PKD1-mutant as well as ADPKD patient-derived hiPSCs can reproduce renal cysts. Further, we demonstrated the possibility of ADPKD kidney organoids serving as drug screening platforms. This newly developed model will contribute to identifying novel therapeutic targets, extending the field of ADPKD research.
Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease

Hao Ding,Linda Xiaoyan Li,Peter C. Harris,Junwei Yang,Xiaogang Li

DOI: https://doi.org/10.1038/s41467-021-24799-x

IF: 16.6

2021-07-27

Nature Communications

Abstract:Abstract Autosomal dominant polycystic kidney disease (ADPKD) is caused by germline mutations of PKD1 or PKD2 on one allele and a somatic mutation inactivating the remaining normal allele. However, if and how null ADPKD gene renal epithelial cells affect the biology and function of neighboring cells, including heterozygous renal epithelial cells, fibroblasts and macrophages during cyst initiation and expansion remains unknown. Here we address this question with a “cystic extracellular vesicles/exosomes theory”. We show that cystic cell derived extracellular vesicles and urinary exosomes derived from ADPKD patients promote cyst growth in Pkd1 mutant kidneys and in 3D cultures. This is achieved by: 1) downregulation of Pkd1 gene expression and upregulation of specific miRNAs, resulting in the activation of PKD associated signaling pathways in recipient renal epithelial cells and tissues; 2) the activation of fibroblasts; and 3) the induction of cytokine expression and the recruitment of macrophages to increase renal inflammation in cystic kidneys. Inhibition of exosome biogenesis/release with GW4869 significantly delays cyst growth in aggressive and milder ADPKD mouse models, suggesting that targeting exosome secretion has therapeutic potential for ADPKD.

multidisciplinary sciences
Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies

Matthew B Lanktree,Amirreza Haghighi,Ighli di Bari,Xuewen Song,York Pei

DOI: https://doi.org/10.2215/CJN.02320220

2021-05-08

Abstract:Autosomal dominant polycystic kidney disease is the most common monogenic cause of ESKD. Genetic studies from patients and animal models have informed disease pathobiology and strongly support a "threshold model" in which cyst formation is triggered by reduced functional polycystin dosage below a critical threshold within individual tubular epithelial cells due to (1) germline and somatic PKD1 and/or PKD2 mutations, (2) mutations of genes (e.g., SEC63, SEC61B, GANAB, PRKCSH, DNAJB11, ALG8, and ALG9) in the endoplasmic reticulum protein biosynthetic pathway, or (3) somatic mosaicism. Genetic testing has the potential to provide diagnostic and prognostic information in cystic kidney disease. However, mutation screening of PKD1 is challenging due to its large size and complexity, making it both costly and labor intensive. Moreover, conventional Sanger sequencing-based genetic testing is currently limited in elucidating the causes of atypical polycystic kidney disease, such as within-family disease discordance, atypical kidney imaging patterns, and discordant disease severity between total kidney volume and rate of eGFR decline. In addition, environmental factors, genetic modifiers, and somatic mosaicism also contribute to disease variability, further limiting prognostication by mutation class in individual patients. Recent innovations in next-generation sequencing are poised to transform and extend molecular diagnostics at reasonable costs. By comprehensive screening of multiple cystic disease and modifier genes, targeted gene panel, whole-exome, or whole-genome sequencing is expected to improve both diagnostic and prognostic accuracy to advance personalized medicine in autosomal dominant polycystic kidney disease.
Generation of Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De Novo Vascular Network

Jian Hui Low,Pin Li,Elaine Guo Yan Chew,Bingrui Zhou,Keiichiro Suzuki,Tian Zhang,Michelle Mulan Lian,Meng Liu,Emi Aizawa,Concepcion Rodriguez Esteban,Kylie Su Mei Yong,Qingfeng Chen,Josep M Campistol,Mingliang Fang,Chiea Chuen Khor,Jia Nee Foo,Juan Carlos Izpisua Belmonte,Yun Xia

DOI: https://doi.org/10.1016/j.stem.2019.06.009

IF: 23.9

2019-09-05

Cell Stem Cell

Abstract:Human pluripotent stem cell-derived kidney organoids recapitulate developmental processes and tissue architecture, but intrinsic limitations, such as lack of vasculature and functionality, have greatly hampered their application. Here we establish a versatile protocol for generating vascularized three-dimensional (3D) kidney organoids. We employ dynamic modulation of WNT signaling to control the relative proportion of proximal versus distal nephron segments, producing a correlative level of vascular endothelial growth factor A (VEGFA) to define a resident vascular network. Single-cell RNA sequencing identifies a subset of nephron progenitor cells as a potential source of renal vasculature. These kidney organoids undergo further structural and functional maturation upon implantation. Using this kidney organoid platform, we establish an in vitro model of autosomal recessive polycystic kidney disease (ARPKD), the cystic phenotype of which can be effectively prevented by gene correction or drug treatment. Our studies provide new avenues for studying human kidney development, modeling disease pathogenesis, and performing patient-specific drug validation.
Deficiency of geranylgeranyl biphosphate synthase in kidney tubules causes cystic kidney disease

Xiaoyan Shao,Kai Wang,Jing Wu,Xiaopen Ma,Yinjuan Zhao,Tao Xu,Chunsun Dai,Furong Zhang,Yuqi Wang,Xianguo Ren,Ke Lu,Zicheng Yin,Baosheng Guo,Changchun Cao,Xianlin Xu,Bin Xue

DOI: https://doi.org/10.1096/fj.202400800R

2024-09-15

Abstract:Polycystic kidney disease (PKD) is a common hereditary kidney disease. Although PKD occurrence is associated with certain gene mutations, its onset regulatory mechanisms are still not well understood. Here, we first report that the key enzyme geranylgeranyl diphosphate synthase (GGPPS) is specifically expressed in renal tubular epithelial cells of mouse kidneys. We aimed to explore the role of GGPPS in PKD. In this study, we established a Ggppsfl/fl:Cdh16cre mouse model and compared its phenotype with that of wild-type mice. A Ggpps-downregulation HK2 cell model was also used to further determine the role of GGPPS. We found that GGPPS was specifically expressed in renal tubular epithelial cells of mouse kidneys. Its expression also increased with age. Low GGPPS expression was observed in human ADPKD tissues. In the Ggppsfl/fl:Cdh16cre mouse model, Ggpps deletion in renal tubular epithelial cells induced the occurrence and development of renal tubule cystic dilation and caused the death of mice after birth due to abnormal renal function. Enhanced proliferation of cyst-lining epithelial cells was also observed after the knockout of Ggpps. These processes were related to the increased rate of Rheb on membrane/cytoplasm and hyperactivation of mTORC1 signaling. In conclusion, the deficiency of GGPPS in kidney tubules induced the formation of renal cysts. It may play a critical role in PKD pathophysiology. A novel therapeutic strategy could be designed according to this work.
Inhibiting centrosome clustering reduces cystogenesis and improves kidney function in autosomal dominant polycystic kidney disease

Tao Cheng,Aruljothi Mariappan,Ewa Langner,Kyuhwan Shim,Jay Gopalakrishnan,Moe R. Mahjoub

DOI: https://doi.org/10.1172/jci.insight.172047

IF: 9.4958

2024-02-23

JCI Insight

Abstract:Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disorder accounting for approximately 5% of patients with renal failure, yet therapeutics for the treatment of ADPKD remain limited. ADPKD tissues display abnormalities in the biogenesis of the centrosome, a defect that can cause genome instability, aberrant ciliary signaling, and secretion of pro-inflammatory factors. Cystic cells form excess centrosomes via a process termed centrosome amplification (CA), which causes abnormal multipolar spindle configurations, mitotic catastrophe, and reduced cell viability. However, cells with CA can suppress multipolarity via "centrosome clustering," a key mechanism by which cells circumvent apoptosis. Here, we demonstrate that inhibiting centrosome clustering can counteract the proliferation of renal cystic cells with high incidences of CA. Using ADPKD human cells and mouse models, we show that preventing centrosome clustering with 2 inhibitors, CCB02 and PJ34, blocks cyst initiation and growth in vitro and in vivo. Inhibiting centrosome clustering activates a p53-mediated surveillance mechanism leading to apoptosis, reduced cyst expansion, decreased interstitial fibrosis, and improved kidney function. Transcriptional analysis of kidneys from treated mice identified pro-inflammatory signaling pathways implicated in CA-mediated cystogenesis and fibrosis. Our results demonstrate that centrosome clustering is a cyst-selective target for the improvement of renal morphology and function in ADPKD.

medicine, research & experimental
Genome editing and kidney health

Nadia Tavakolidakhrabadi,Francesco Aulicino,Carl May,Moin A Saleem,Imre Berger,Gavin I Welsh

DOI: https://doi.org/10.1093/ckj/sfae119

2024-04-17

Clinical Kidney Journal

Abstract:Abstract Genome editing technologies, CRISPR/Cas in particular, have revolutionized the field of genetic engineering, providing promising avenues for treating various genetic diseases. Chronic Kidney Disease (CKD), a significant health concern affecting millions of individuals worldwide, can arise from either monogenic or polygenic mutations. With recent advancements in genomic sequencing, valuable insights into disease-causing mutations can be obtained, allowing for the development of new treatments for these genetic disorders. CRISPR-based treatments have emerged as potential therapies, especially for monogenic diseases, offering the ability to correct mutations and eliminate disease phenotypes. Innovations in genome editing have led to enhanced efficiency, specificity, and ease of use, surpassing earlier editing tools such as zinc-finger nucleases and TALENs. Two prominent advancements in CRISPR-based gene editing are prime editing and base editing. Prime editing allows precise and efficient genome modifications without inducing double-stranded DNA breaks, while base editing enables targeted changes to individual nucleotides in both RNA and DNA, promising disease correction in absence of double strand DNA breaks (DSBs). These technologies have the potential to treat genetic kidney diseases through specific correction of disease-causing mutations, such as somatic mutations in PKD1 and PKD2 for polycystic kidney disease (PKD), NPHS1, NPHS2, and TRPC6 for Focal Segmental Glomerulosclerosis (FSGS), COL4A3, COL4A4, and COL4A5 for Alport Syndrome, SLC3A1 and SLC7A9 for Cystinuria, and even VHL for Renal Cell Carcinoma (RCC). Apart from editing DNA sequence, CRISPR-mediated epigenome editing offers a cost-effective method for targeted treatment providing new avenues for therapeutic development given that epigenetic modifications are associated with the development of various kidney disorders. However, there are challenges to overcome, these include developing efficient delivery methods, improving safety, and reducing off-target effects. Efforts to improve CRISPR/Cas technologies involve optimizing delivery vectors, employing viral and non-viral approaches, and minimizing immunogenicity. With research in animal models providing promising results in rescuing the expression of wild type podocin in mouse models of nephrotic syndrome, and successful clinical trials in the early stages of various disorders, including cancer immunotherapy, there is hope for successful translation of genome editing to kidney diseases.

urology & nephrology
Identification of ADPKD-Related Genes and Pathways in Cells Overexpressing PKD2

Zhe Zhang,Yanna Dang,Zizengceng Wang,Huanan Wang,Yuchun Pan,Jin He

DOI: https://doi.org/10.3390/genes11020122

IF: 4.141

2020-01-01

Genes

Abstract:Consistent with the gene dosage effect hypothesis, renal cysts can arise in transgenic murine models overexpressing either PKD1 or PKD2, which are causal genes for autosomal dominant polycystic kidney disease (ADPKD). To determine whether PKD gene overexpression is a universal mechanism driving cystogenesis or is merely restricted to rodents, other animal models are required. Previously, we failed to observe any renal cysts in a transgenic porcine model of PKD2 overexpression partially due to epigenetic silencing of the transgene. Thus, to explore the feasibility of porcine models and identify potential genes/pathways affected in ADPKD, LLC-PK1 cells with high PKD2 expression were generated. mRNA sequencing (RNA-seq) was performed, and MYC, IER3, and ADM were found to be upregulated genes common to the different PKD2 overexpression cell models. MYC is a well-characterized factor contributing to cystogenesis, and ADM is a biomarker for chronic kidney disease. Thus, these genes might be indicators of disease progression. Additionally, some ADPKD-associated pathways, e.g., the mitogen-activated protein kinase (MAPK) pathway, were enriched in the cells. Moreover, gene ontology (GO) analysis demonstrated that proliferation, apoptosis, and cell cycle regulation, which are hallmarks of ADPKD, were altered. Therefore, our experiment identified some biomarkers or indicators of ADPKD, indicating that high PKD2 expression would likely drive cystogenesis in future porcine models.
A Rare Deep Intronic Mutation of PKHD1 Gene, C.8798-459 C > A, Causes Autosomal Recessive Polycystic Kidney Disease by Pseudoexon Activation

Jing Chen,Na Ma,Xiaomeng Zhao,Wen Li,Qianjun Zhang,Shimin Yuan,Yue-Qiu Tan,Guangxiu Lu,Ge Lin,Juan Du

DOI: https://doi.org/10.1038/s10038-018-0550-8

2019-01-01

Journal of Human Genetics

Abstract:Autosomal recessive polycystic kidney disease (ARPKD), is a rare hepatorenal fibrocystic disorder primarily associated with progressive growth of multiple cysts in the kidneys causing progressive loss of renal function. The disease is linked to mutations in the PKHD1 gene. In this study, we describe the gene diagnosis and prenatal diagnosis for a consanguineous family with two fetuses diagnosed with polycystic kidney disease by fetal sonography during the pregnancy. Sequence analysis of cDNA synthesized from the PKHD1 mRNA of the second induced fetus identified a 111-nucleotide insert at the junction of exon 56 and 57 that originated from intervening sequence (IVS) 56. Further genomic sequencing of IVS 56 of the PKHD1 gene identified a rare homozygous deep intronic mutation (c.8798-459 C > A), which was inherited from the parents and not detectable in 100 unrelated control subjects. Moreover, we explored the pathogenicity of this deep intronic mutation by conducting a minigene splicing assay experiment, which demonstrated that the mutation causes a pseudoexon insertion, which results in a frameshift followed by a premature termination codon in exon 57. Eventually, the parents had a healthy baby by undergoing prenatal genetic diagnosis based on the targeted detection of the intron mutation. The newly identified deep intronic mutation is associated with a rare mechanism of abnormal splicing that expands the spectrum of known PKHD1 gene mutations. It can be used in evidence-based genetic and reproductive counseling for families with ARPKD.
Genetics and mechanisms of hepatic cystogenesis

L F M van de Laarschot,J P H Drenth

DOI: https://doi.org/10.1016/j.bbadis.2017.08.003

Abstract:Polycystic liver disease (PLD) is a heterogeneous genetic condition. PKD1 and PKD2 germline mutations are found in patients with autosomal dominant polycystic kidney disease (ADPKD). Autosomal dominant polycystic liver disease (ADPLD) is associated with germline mutations in PRKCSH, SEC63, LRP5, and recently ALG8 and SEC61. GANAB mutations are found in both patient groups. Loss of heterozygosity of PLD-genes in cyst epithelium contributes to the development of hepatic cysts. A genetic interaction network is implied in hepatic cystogenesis that connects the endoplasmic glycoprotein control mechanisms and polycystin expression and localization. Wnt signalling could be the major downstream signalling pathway that results in hepatic cyst growth. PLD in ADPLD and ADPKD probably results from changes in one common final pathway that initiates cyst growth. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease

Nelly M. Cruz,Xuewen Song,Stefan M. Czerniecki,Ramila E. Gulieva,Angela J. Churchill,Yong Kyun Kim,Kosuke Winston,Linh M. Tran,Marco A. Diaz,Hongxia Fu,Laura S. Finn,York Pei,Jonathan Himmelfarb,Benjamin S. Freedman

DOI: https://doi.org/10.1038/nmat4994

IF: 41.2

2017-10-02

Nature Materials

Abstract:Tissue mimics are of great interest in understanding diseases. Here, organoids were developed that resemble polycystic kidney disease cysts and it was demonstrated how material environment and adhesion can affect cystogenesis and disease progression.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter
Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery

Ken Hiratsuka,Tomoya Miyoshi,Katharina T. Kroll,Navin R. Gupta,M. Todd Valerius,Thomas Ferrante,Michifumi Yamashita,Jennifer A. Lewis,Ryuji Morizane

DOI: https://doi.org/10.1126/sciadv.abq0866

IF: 13.6

2022-09-22

Science Advances

Abstract:Organoids serve as a novel tool for disease modeling in three-dimensional multicellular contexts. Static organoids, however, lack the requisite biophysical microenvironment such as fluid flow, limiting their ability to faithfully recapitulate disease pathology. Here, we unite organoids with organ-on-a-chip technology to unravel disease pathology and develop therapies for autosomal recessive polycystic kidney disease. PKHD1 -mutant organoids-on-a-chip are subjected to flow that induces clinically relevant phenotypes of distal nephron dilatation. Transcriptomics discover 229 signal pathways that are not identified by static models. Mechanosensing molecules, RAC1 and FOS, are identified as potential therapeutic targets and validated by patient kidney samples. On the basis of this insight, we tested two U.S. Food and Drug Administration–approved and one investigational new drugs that target RAC1 and FOS in our organoid-on-a-chip model, which suppressed cyst formation. Our observations highlight the vast potential of organoid-on-a-chip models to elucidate complex disease mechanisms for therapeutic testing and discovery.

multidisciplinary sciences
Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease

Priyanka Pandey,Shan Qin,Jacqueline Ho,Jing Zhou,Jordan A Kreidberg

DOI: https://doi.org/10.1186/1752-0509-5-56

2011-04-25

Abstract:Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by cyst formation throughout the kidney parenchyma. It is caused by mutations in either of two genes, PKD1 and PKD2. Mice that lack functional Pkd1 (Pkd1⁻/⁻), develop rapidly progressive cystic disease during embryogenesis, and serve as a model to study human ADPKD. Genome wide transcriptome reprogramming and the possible roles of micro-RNAs (miRNAs) that affect the initiation and progression of cyst formation in the Pkd1⁻/⁻ have yet to be studied. miRNAs are small, regulatory non-coding RNAs, implicated in a wide spectrum of biological processes. Their expression levels are altered in several diseases including kidney cancer, diabetic nephropathy and PKD. Results: We examined the molecular pathways that modulate renal cyst formation and growth in the Pkd1⁻/⁻ model by performing global gene-expression profiling in embryonic kidneys at days 14.5 and 17.5. Gene Ontology and gene set enrichment analysis were used to identify overrepresented signaling pathways in Pkd1⁻/⁻ kidneys. We found dysregulation of developmental, metabolic, and signaling pathways (e.g. Wnt, calcium, TGF-β and MAPK) in Pkd1⁻/⁻ kidneys. Using a comparative transcriptomics approach, we determined similarities and differences with human ADPKD: ~50% overlap at the pathway level among the mis-regulated pathways was observed. By using computational approaches (TargetScan, miRanda, microT and miRDB), we then predicted miRNAs that were suggested to target the differentially expressed mRNAs. Differential expressions of 9 candidate miRNAs, miRs-10a, -30a-5p, -96, -126-5p, -182, -200a, -204, -429 and -488, and 16 genes were confirmed by qPCR. In addition, 14 candidate miRNA:mRNA reciprocal interactions were predicted. Several of the highly regulated genes and pathways were predicted as targets of miRNAs. Conclusions: We have described global transcriptional reprogramming during the progression of PKD in the Pkd1⁻/⁻ model. We propose a model for the cascade of signaling events involved in cyst formation and growth. Our results suggest that several miRNAs may be involved in regulating signaling pathways in ADPKD. We further describe novel putative miRNA:mRNA signatures in ADPKD, which will provide additional insights into the pathogenesis of this common genetic disease in humans.
Rapid target validation in a Cas9-inducible hiPSC derived kidney model

Yasaman Shamshirgaran,Anna Jonebring,Anna Svensson,Isabelle Leefa,Mohammad Bohlooly-Y,Mike Firth,Kevin J Woollard,Alexis Hofherr,Ian M Rogers,Ryan Hicks

DOI: https://doi.org/10.1038/s41598-021-95986-5

2021-08-16

Abstract:Recent advances in induced pluripotent stem cells (iPSCs), genome editing technologies and 3D organoid model systems highlight opportunities to develop new in vitro human disease models to serve drug discovery programs. An ideal disease model would accurately recapitulate the relevant disease phenotype and provide a scalable platform for drug and genetic screening studies. Kidney organoids offer a high cellular complexity that may provide greater insights than conventional single-cell type cell culture models. However, genetic manipulation of the kidney organoids requires prior generation of genetically modified clonal lines, which is a time and labor consuming procedure. Here, we present a methodology for direct differentiation of the CRISPR-targeted cell pools, using a doxycycline-inducible Cas9 expressing hiPSC line for high efficiency editing to eliminate the laborious clonal line generation steps. We demonstrate the versatile use of genetically engineered kidney organoids by targeting the autosomal dominant polycystic kidney disease (ADPKD) genes: PKD1 and PKD2. Direct differentiation of the respective knockout pool populations into kidney organoids resulted in the formation of cyst-like structures in the tubular compartment. Our findings demonstrated that we can achieve > 80% editing efficiency in the iPSC pool population which resulted in a reliable 3D organoid model of ADPKD. The described methodology may provide a platform for rapid target validation in the context of disease modeling.
Scar endometrioma.

C. Gerrand

IF: 2.632

The Surgeon

Abstract:
Mianserin and Complete Heart Block

K. Hla,O. Boyd

DOI: https://doi.org/10.1177/096032718700600510

1987-09-01

Human Toxicology

Abstract:Cardiac complications are common in tricyclic antidepressant poisoning, but are rare with overdose of mianserin, which is a tetracyclic antidepressant. We report a case in which repeated episodes of complete heart block occurred following overdose with mianserin.
Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys.

Bo Hu,Xiusheng He,Ao Li,Qingchao Qiu,Cunxi Li,Dan Liang,Ping Zhao,Jie Ma,Robert J Coffey,Qimin Zhan,Guanqing Wu

DOI: https://doi.org/10.1016/j.yexcr.2010.09.012

IF: 4.145

2011-01-01

Experimental Cell Research

Abstract:Mutations in the PKHD1 gene result in autosomal recessive polycystic kidney disease (ARPKD) in humans. To determine the molecular mechanism of the cystogenesis in ARPKD, we recently generated a mouse model for ARPKD that carries a targeted mutation in the mouse orthologue of human PKHD1. The homozygous mutant mice display hepatorenal cysts whose phenotypes are similar to those of human ARPKD patients. By littermates of this mouse, we developed two immortalized renal collecting duct cell lines with Pkhd1 and two without. Under nonpermissive culture conditions, the Pkhd1−/− renal cells displayed aberrant cell–cell contacts and tubulomorphogenesis. The Pkhd1−/− cells also showed significantly reduced cell proliferation and elevated apoptosis. To validate this finding in vivo, we examined proliferation and apoptosis in the kidneys of Pkhd1−/− mice and their wildtype littermates. Using proliferation (PCNA and Histone-3) and apoptosis (TUNEL and caspase-3) markers, similar results were obtained in the Pkhd1−/− kidney tissues as in the cells. To identify the molecular basis of these findings, we analyzed the effect of Pkhd1 loss on multiple putative signaling regulators. We demonstrated that the loss of Pkhd1 disrupts multiple major phosphorylations of focal adhesion kinase (FAK), and these disruptions either inhibit the Ras/C-Raf pathways to suppress MEK/ERK activity and ultimately reduce cell proliferation, or suppress PDK1/AKT to upregulate Bax/caspase-9/caspase-3 and promote apoptosis. Our findings indicate that apoptosis may be a major player in the cyst formation in ARPKD, which may lead to new therapeutic strategies for human ARPKD.
Defects of renal tubular homeostasis and cystogenesis in the Pkhd1 knockout

Julia C. Fox,Susanne T. Hahnenstein,Fatima Hassan,Andrea Grund,Dieter Haffner,Wolfgang H. Ziegler

DOI: https://doi.org/10.1016/j.isci.2024.109487

IF: 5.8

2024-04-01

iScience

Abstract:Loss of PKHD1-gene function causes autosomal recessive polycystic kidney disease (ARPKD) characterized by bilateral severely enlarged kidneys and congenital liver fibrosis requiring kidney replacement therapy most frequently during childhood. Studies using renal tissue from ARPKD patients suggest cyst promotion by suppressed hippo activity and enhanced Src/STAT3-signaling. We address renal homeostasis in female Pkhd1-knockout mice, aged 3 to 9 months, and observe features in common with late-onset ARPKD. Pkhd1-knockout animals show significant increase in kidney and liver weight with preserved organ function. Kidney cyst formation of the S3 segment is accompanied by macrophage recruitment and fibrotic remodeling. Cystic epithelia display increased proliferation, high levels of nuclear YAP/TAZ, and enhanced apoptosis. Y705-phosphorylated STAT3 is strongly enhanced in nuclei of cyst-lining epithelia. In this Pkhd1-deficiency model, stressed cystic epithelia expose the altered signaling pattern and disease-related mechanisms deemed relevant to human ARPKD, and thus may allow identification of therapeutic targets of this disease.

multidisciplinary sciences

Optimization of cosmesis in parathyroidectomy

Establishment of transgenic pigs overexpressing human <i>PKD2-D511V</i> mutant

Human iPSC-derived renal collecting duct organoid model cystogenesis in ADPKD

A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs

Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease

Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies

Generation of Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De Novo Vascular Network

Deficiency of geranylgeranyl biphosphate synthase in kidney tubules causes cystic kidney disease

Inhibiting centrosome clustering reduces cystogenesis and improves kidney function in autosomal dominant polycystic kidney disease

Genome editing and kidney health

Identification of ADPKD-Related Genes and Pathways in Cells Overexpressing PKD2

A Rare Deep Intronic Mutation of PKHD1 Gene, C.8798-459 C > A, Causes Autosomal Recessive Polycystic Kidney Disease by Pseudoexon Activation

Genetics and mechanisms of hepatic cystogenesis

Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease

Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery

Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease

Rapid target validation in a Cas9-inducible hiPSC derived kidney model

Scar endometrioma.

Mianserin and Complete Heart Block

Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys.

Defects of renal tubular homeostasis and cystogenesis in the Pkhd1 knockout